Toronto Western Hospital

Running trials

• Recruiting

  Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

  NCT07227896· AbbVie· Source

• Recruiting

  A Post Authorization Registry Study of Participants Treated With LEQEMBI

  NCT07762092· Eisai Limited· Source

• Recruiting

  Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)

  NCT07569198· Phase 2· Joshua Rosenblat· Source

• Enrolling by invitation

  Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression

  NCT07737990· Joshua Rosenblat· Source

• Recruiting

  Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares

  NCT07245732· Phase 4· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Sustained Mood Improvement With Laughing Gas Exposure

  NCT07262008· Phase 3· Women's College Hospital· Source

• Active, not recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)

  NCT07234942· Phase 1· Hoffmann-La Roche· Source

• Recruiting

  LIFUS For Neurological Disorders

  NCT07417280· University Health Network, Toronto· Source

• Recruiting

  Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

  NCT07107022· Penumbra Inc.· Source

• Recruiting

  Levetiracetam for Persons at Risk for Alzheimer's Disease

  NCT07477431· Phase 2· Sunnybrook Health Sciences Centre· Source

• Recruiting

  A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  NCT07175285· Bristol-Myers Squibb· Source

• Active, not recruiting

  A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)

  NCT07133633· Phase 2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

  NCT07169578· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

  NCT07033494· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Deep Brain Stimulation of the Pedunculopontine Nucleus for Alzheimer's Disease

  NCT06936124· University Health Network, Toronto· Source

• Enrolling by invitation

  Brain-Machine Interface for Freezing of Gait

  NCT06642519· University of Toronto· Source

• Active, not recruiting

  A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT06795048· Phase 4· Hoffmann-La Roche· Source

• Not yet recruiting

  Effectiveness of AV-stimulation in Immersive VR to Improve Visual Perception and Driving Performance

  NCT05703360· University Health Network, Toronto· Source

• Recruiting

  Theta Burst Transcranial Focused Ultrasound as a Novel Treatment for Cervical Dystonia

  NCT07690514· Robert Chen· Source

• Recruiting

  Directional Bilateral Thalamic Patterned Stimulation (Chronos)

  NCT06325852· Alfonso Fasano· Source

• Recruiting

  Pedunculopontine Nucleus Transcranial Ultrasound Stimulation as a Treatment of Freezing of Gait in Parkinson's Disease

  NCT07695233· Robert Chen· Source

• Recruiting

  Perioperative Vitamin C to Reduce Persistent Pain After Total Knee Arthroplasty

  NCT06123715· Phase 3· University Health Network, Toronto· Source

• Recruiting

  Effects of Excitatory and Inhibitory LIFUS of GPi in Parkinsonian Patients Without DBS

  NCT07846007· University Health Network, Toronto· Source

• Recruiting

  Emotion and Memory in Chronic Neuropathic Pain

  NCT06518421· University Health Network, Toronto· Source

• Active, not recruiting

  Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

  NCT06341426· Phase 2· University Health Network, Toronto· Source

• Recruiting

  Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

  NCT07265596· Phase 2· Michael J. Fox Foundation for Parkinson's Research· Source

• Recruiting

  International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

  NCT06174727· Montefiore Medical Center· Source

• Active, not recruiting

  DBS Virtual Learning Experience

  NCT06436313· University of Toronto· Source

• Active, not recruiting

  Towards Noninvasive DBS of the Basal Ganglia in Parkinson's Disease Using TUS

  NCT06232629· University Health Network, Toronto· Source

• Active, not recruiting

  Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

  NCT05843643· Phase 3· AbbVie· Source

• Enrolling by invitation

  Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

  NCT05897957· BlueRock Therapeutics· Source

• Recruiting

  E-field Guided iTBS for Treatment Resistant Depression

  NCT05583747· Centre for Addiction and Mental Health· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Biogen· Source

• Recruiting

  Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches

  NCT05306899· Phase 3· University Health Network, Toronto· Source

• Recruiting

  Biofeedback for Hemianopia Vision Rehabilitation

  NCT05397873· University Health Network, Toronto· Source

• Recruiting

  Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study

  NCT04973397· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study of Guselkumab in Participants With Active Psoriatic Arthritis

  NCT04882098· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease

  NCT04777331· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  Physiotherapy and Deep Brain Stimulation in Parkinson's Disease

  NCT04953637· University of Toronto· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Parkinson's Foundation· Source

• Recruiting

  Evaluating Oral Peri-operative Acetylsalicylic Acid in Subjects Undergoing Endovascular Coiling-only of Unruptured Brain Aneurysms

  NCT04192955· Phase 3· University of Calgary· Source

• Recruiting

  PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

  NCT04477785· Michael J. Fox Foundation for Parkinson's Research· Source

• Recruiting

  Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

  NCT03474029· Phase 2/3· Centers for Disease Control and Prevention· Source

• Active, not recruiting

  ExAblate Pallidotomy for Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Parkinson's Disease

  NCT03319485· InSightec· Source

• Active, not recruiting

  Multicenter Phase II Study of Transanal TME (taTME)

  NCT03144765· Icahn School of Medicine at Mount Sinai· Source

• Active, not recruiting

  ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders

  NCT02252380· InSightec· Source

• Recruiting

  Canadian Fabry Disease Initiative (CFDI) National Registry

  NCT00455104· Canadian Fabry Research Consortium· Source

Showing 50 of 51.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Parkinson disease9 recruiting
• Alzheimer disease5 recruiting
• Depression4 recruiting
• Stroke3 recruiting
• Brain aneurysm2 recruiting
• Dystonia2 recruiting
• Essential tremor2 recruiting
• Lupus (SLE)2 recruiting
• Bipolar disorder1 recruiting
• Borderline personality disorder1 recruiting
• Coronary artery disease1 recruiting
• Epilepsy1 recruiting
• Fabry disease1 recruiting
• Migraine1 recruiting
• Mild cognitive impairment1 recruiting
• Osteoarthritis1 recruiting
• Rheumatoid arthritis1 recruiting
• Spinal cord injury1 recruiting
• Trigeminal neuralgia1 recruiting
• Tuberculosis1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  Evaluating the Impact of Virtual Reality Exposure Therapy on Epilepsy/Seizure-Specific Interictal Anxiety

  NCT06028945· University Health Network, Toronto· Source

• Completed

  Effects of Unblocking the Full Potential of Percept PC IPG

  NCT06127771· University of Toronto· Source

• Terminated

  Fenfluramine for Adult Dravet Patients

  NCT05560282· Phase 3· University Health Network, Toronto· Source

• Completed

  Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression

  NCT05339074· Phase 2· Joshua Rosenblat· Source

• Completed

  Ketamine for Treatment-Resistant Bipolar Disorder

  NCT05004896· Phase 2· Joshua Rosenblat· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Completed

  A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

  NCT05348785· Phase 2· Biogen· Source

• Completed

  Study of BOTOX Injections to Assess Change in Disease Symptoms in Adult Participants With Upper Limb Essential Tremor

  NCT05216250· Phase 2· AbbVie· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Marinus Pharmaceuticals· Source

• Completed

  Semaglutide for the Treatment of Cognitive Dysfunction in Major Depressive Disorder

  NCT04466345· Phase 2· University Health Network, Toronto· Source

• Completed

  The Impact of Interscalene Block on Sleep Disordered Breathing

  NCT03718858· Women's College Hospital· Source

• Completed

  Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

  NCT04802733· Phase 1· BlueRock Therapeutics· Source

• Completed

  Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease

  NCT04547712· MedtronicNeuro· Source

• Completed

  Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

  NCT04295538· Phase 2· AbbVie· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis

  NCT04169373· Phase 3· AbbVie· Source

• Completed

  ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease

  NCT03622905· Functional Neuromodulation Ltd· Source

• Completed

  Study to Evaluate Cerebral AneurysmFlow Results in Occlusion

  NCT03663257· Philips Clinical & Medical Affairs Global· Source

• Completed

  Tele-CBT Following Bariatric Surgery: Randomized Control Trial

  NCT03315247· University Health Network, Toronto· Source

• Recruiting

  Primary Tumor Research and Outcomes Network

  NCT02790983· AO Innovation Translation Center· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Parkinson disease80 works · 19 trials
• Dystonia30 works · 4 trials
• Lupus (SLE)27 works · 3 trials
• Spinal cord injury19 works · 2 trials
• Psoriatic arthritis19 works · 2 trials
• Delirium13 works · 0 trials
• Essential tremor11 works · 4 trials
• Tourette syndrome11 works · 0 trials
• Frontotemporal dementia8 works · 0 trials
• Brain aneurysm7 works · 3 trials
• Fibromyalgia5 works · 0 trials
• Multiple system atrophy4 works · 0 trials